| News
NBE-Therapeutics raises 22 million dollars
10.01.2020
The Basel biotech company NBE-Therapeutics has successfully closed a series C financing round. The funds raised will help the company develop its leading product candidate to fight cancer.

Research (Img: FreeImages.com)
The Series C financing round was led by current investors – the Boehringer Ingelheim Venture Fund and the PPF Group, announced a statement from NBE-Therapeutics. All current private investors were involved.
A total of 22 million dollars was raised, which NBE-Therapeutics will primarily use to develop its product candidate NBE-002. The first clinical trial on humans suffering from breast cancer or lung cancer is expected to take place in the summer. There are also plans to strengthen the development team, management and board with the funds.
NBE-Therapeutics develops antibody drug conjugates that stimulate the immune system. These are known as immune-stimulatory antibody drug conjugate/iADC. Unlike chemotherapy, they target only damaging cells in cancer therapy. To support its work, the company developed a platform.
“We highly value the trust our current shareholders have placed in both our technology platform and lead iADC program, through which we have been able to develop highly effective oncology treatments,” commented Ulf Grauwunder, founder and CEO of NBE-Therapeutics.
Member of the Board Jens Hennecke praised the progression of the biotech company, saying that it is now entering its next phase in becoming a leading clinical-stage company in iADC. Hennecke represents the investor PPF Group, whose subsidiary Sotio recently opened an office in the Technologiepark Basel with support from BaselArea.swiss. NBE-Therapeutics’ headquarters are also in the Technologiepark Basel.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Space Pharmaceuticals establishes presence in Basel
Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...
Read MoreNextImmune to benefit from Venture Kick financing
The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...
Read MoreOECD impressed by the canton of Jura’s innovation system
The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...
Read Moreti&m opens branch in Basel
ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...
Read MoreWhat can artificial intelligence do for health?
Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...
Read MoreEconomic promotion agency creates 55 new jobs in Jura
The economic promotion agency of the canton of Jura supported a total of 26 companies in founding, establishing a presence...
Read More